Association of adult attention deficit hyperactivity disorder subtypes and response to methylphenidate HCL treatment: A magnetic resonance spectroscopy study

被引:4
|
作者
Unal, Gonca Ayse [1 ]
Kenar, Ayse Nur Inci [2 ]
Herken, Hasan [2 ]
Kiroglu, Yilmaz [3 ]
机构
[1] Kozan State Hosp, Psychiat Clin, Adana, Turkey
[2] Pamukkale Univ, Sch Med, Dept Psychiat, TR-20070 Denizli, Turkey
[3] Pamukkale Univ, Sch Med, Dept Radiol, TR-20070 Denizli, Turkey
关键词
Adult ADHD; Subtype; Methylphenidate; Magnetic resonance spectroscopy; UTAH RATING-SCALE; DEFICIT/HYPERACTIVITY DISORDER; MR SPECTROSCOPY; CHILDREN; GLUTAMATE/GLUTAMINE; ADOLESCENTS; VALIDITY; CREATINE;
D O I
10.1016/j.neulet.2015.08.006
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The effects of methylphenidate (MPH) treatment on N-acetyl aspartate (NAA), choline and creatine are being examined in individuals with different subtypes of attention deficit hyperactivity disorder (ADHD). Sixty ADHD subjects were included into the study aging between 18 and 60 years. Levels of NAA, creatine and choline in anterior cingulate cortex, cerebellum, striatum and dorsolateral prefrontal cortex were measured with magnetic resonance spectroscopy. Then, 10 mg oral MPH was given to the subjects and the same metabolite levels were measured after an interval of 30 min. Distribution of the patients according to the ADHD subtypes was as follows: 21 of them (35.0%) were in the inattentive type, 11 of them (18.3%) were in the hyperactive type and 28 of them were (46.7%) in the combined type. Changes of brain metabolite levels after MPH were found not to be statistically significantly different between the subtypes. The increase of choline levels after MPH compared to the levels of choline before MPH in striatum in the combined type patients were statistically significant. No clear association was found between ADHD subtypes and changes of brain metabolites with use of MPH in adult ADHD. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:188 / 192
页数:5
相关论文
共 50 条
  • [41] Clinical use of 30:70 controlled-release methylphenidate in the treatment of attention deficit hyperactivity disorder
    Mardomingo-Sanz, Maria J.
    REVISTA DE NEUROLOGIA, 2012, 55 (06) : 359 - 369
  • [42] Risperidone Versus Methylphenidate in Treatment of Preschool Children With Attention-Deficit Hyperactivity Disorder
    Arabgol, Fariba
    Panaghi, Leily
    Nikzad, Vahid
    IRANIAN JOURNAL OF PEDIATRICS, 2015, 25 (01)
  • [43] OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder
    McBurnett, Keith
    Starr, H. Lynn
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (02) : 315 - 324
  • [44] Methylphenidate prescription in adult attention deficit disorder with or without hyperactivity (ADHD): A pharmacovigilance study
    Salvez, C.
    Carton, L.
    Gautier, S.
    Potey, C.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 : 86 - 86
  • [45] Electroencephalographic biomarkers as predictors of methylphenidate response in attention-deficit/hyperactivity disorder
    Arns, Martijn
    Vollebregt, Madelon A.
    Palmer, Donna
    Spooner, Chris
    Gordon, Evian
    Kohn, Michael
    Clarke, Simon
    Elliott, Glen R.
    Buitelaar, Jan K.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2018, 28 (08) : 881 - 891
  • [46] Integrative genomic analysis of methylphenidate response in attention-deficit/hyperactivity disorder
    Pagerols, Mireia
    Richarte, Vanesa
    Sanchez-Mora, Cristina
    Rovira, Paula
    Soler Artigas, Maria
    Garcia-Martinez, Iris
    Calvo-Sanchez, Eva
    Corrales, Montse
    da Silva, Bruna Santos
    Mota, Nina Roth
    Victor, Marcelo Moraes
    Rohde, Luis Augusto
    Grevet, Eugenio Horacio
    Dotto Bau, Claiton Henrique
    Cormand, Bru
    Casas, Miguel
    Antoni Ramos-Quiroga, Josep
    Ribases, Marta
    SCIENTIFIC REPORTS, 2018, 8
  • [47] Association of salivary dehydroepiandrosterone levels and symptoms in patients with attention deficit hyperactivity disorder during six months of treatment with methylphenidate
    Wang, Liang-Jen
    Hsiao, Cheng-Cheng
    Huang, Yu-Shu
    Chiang, Yuan-Lin
    Ree, Shao-Chun
    Chen, Yi-Chih
    Wu, Ya-Wen
    Wu, Chih-Ching
    Shang, Zong-Yi
    Chen, Chih-Ken
    PSYCHONEUROENDOCRINOLOGY, 2011, 36 (08) : 1209 - 1216
  • [48] METHYLPHENIDATE AND SHORT-TERM MEMORY IN YOUNG FEMALES WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER. A STUDY USING FUNCTIONAL MAGNETIC RESONANCE IMAGING
    Gonzalez-Garrido, A. A.
    Barrios, F. A.
    de la Serna-Tuya, J. M.
    Cocula-Leon, H.
    Gomez-Velazquez, F. R.
    REVISTA DE NEUROLOGIA, 2009, 48 (10) : 509 - 514
  • [49] Clinical and cognitive response to extended-release methylphenidate (MedikinetA®) in attention deficit/hyperactivity disorder: Efficacy evaluation
    Fernandez-Jaen, Alberto
    Martin Fernandez-Mayoralas, Daniel
    Pardos, Alexandra
    Calleja-Perez, Beatriz
    Munoz Jareno, Nuria
    ADVANCES IN THERAPY, 2009, 26 (12) : 1097 - 1110
  • [50] Assessment of Methylphenidate Prescriptions Written for the Treatment of Attention-Deficit/Hyperactivity Disorder
    Akici, Ahmet
    Gelal, Ayse
    Demircan, Dilek
    Tiskaoglu, Ramazan
    Topcus, Ibrahim
    Yilmaz, Huseyin
    KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, 2013, 23 (01): : 42 - 48